Sotoracib (AMG510) market pricing and global sales trends

Sotoracib (AMG510), this targeted drug leading a new era of anti-cancer, brings hope to many cancer patients with its unique KRAS G12C protein inhibition mechanism. The KRAS G12C mutation is widely present in a variety of cancers, especially in non-small cell lung cancer (NSCLC), and sotoracib is a precision treatment drug designed to target this mutation.

Compared with traditional chemotherapy drugs, sotoraxib has won widespread attention in the market for its high specificity and low toxic and side effects. Its excellent efficacy and safety demonstrated in clinical trials have given the medical community high hopes for it, believing that it is expected to completely change the treatment status of KRAS G12C mutated malignant tumors.

However, for domestic patients, the original version of the drug has not yet been marketed in China, and therefore is not included in medical insurance. This leaves domestic patients to purchase only through overseas channels, and price has become a major obstacle. In Hong Kong, the original research version of sotorasibu120mg*240 tablets is priced at more than 30,000 yuan; in Europe, the price of the drug of the same specification is also more than 30,000 yuan, and may change due to exchange rate fluctuations.

There are also some more affordable generic drug options on the market. These generic drugs are basically the same as the original drugs in terms of ingredients, but their prices are quite different. For example, the price of 120mg*56 tablets of sotolasibu produced by Lucius Pharmaceutical Factory in Laos is only more than 1,000 yuan per box; while the price of similar products from Daxiong Pharmaceutical is more than 2,000 yuan per box. The emergence of these generic drugs has undoubtedly provided more choices for patients who cannot afford the high prices of original drugs.